Get the Stockscreener App
14.00
3.45%
-0.50
After Hours:
14.00
Bicara Therapeutics Inc stock is traded at $14.00, with a volume of 514.34K.
It is down -3.45% in the last 24 hours and up +32.45% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$14.50
Open:
$14.12
24h Volume:
514.34K
Relative Volume:
1.03
Market Cap:
$807.68M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.47%
1M Performance:
+32.45%
6M Performance:
-44.42%
1Y Performance:
+0.00%
1-Day Range:
$13.76
$14.40
1-Week Range:
$13.28
$15.61
52-Week Range:
$8.91
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-785-8308
Address
245 MAIN STREET, CAMBRIDGE
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
14.00 | 807.68M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Invesco Ltd. Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $32.43 - Defense World
A new trading data show Bicara Therapeutics Inc (BCAX) is showing positive returns. - Sete News
Legal & General Group Plc Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc [BCAX] Shares Fall -3.43 % on Wednesday - knoxdaily.com
A closer look at Bicara Therapeutics Inc (BCAX)’s stock price trends - uspostnews.com
Wedbush Lifts Earnings Estimates for Bicara Therapeutics - Defense World
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa Drives Buy Rating Amid Encouraging Clinical Data and Growth Opportunities - TipRanks
Cautious Outlook on Bicara Therapeutics Inc. Amid Efficacy and Safety Concerns for Ficerafusp - TipRanks
Promising Clinical Trial Results Boost Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 - GlobeNewswire
Riding the Waves: A Guide to Investing in BCAX Stock - investchronicle.com
JPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Here’s Why - Defense World
Bicara Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Bicara Therapeutics Inc (NASDAQ: BCAX) Is The Among Hot Stock Right Now - Stocksregister
Geode Capital Management LLC Acquires 418,003 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara to present updated trial data at ASCO Meeting - Investing.com
Bicara to present updated trial data at ASCO Meeting By Investing.com - Investing.com South Africa
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Bicara Therapeutics to Present Updated Phase 1/1b Clinical Trial Data for Ficerafusp Alfa at ASCO 2025 - Nasdaq
Bicara Stock: Innovative Precision Tumor Targeting (NASDAQ:BCAX) - Seeking Alpha
Wells Fargo & Company Initiates Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
Vanguard Group Inc. Acquires 1,020,528 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics initiated with an Underweight at Wells Fargo - TipRanks
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target - marketscreener.com
Corebridge Financial Inc. Takes $167,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
HC Wainwright Issues Pessimistic Forecast for BCAX Earnings - Defense World
Promising Developments and Market Opportunities Drive Buy Rating for Bicara Therapeutics - TipRanks
HC Wainwright Issues Pessimistic Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price - The AM Reporter
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from Brokerages - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Given New $44.00 Price Target at HC Wainwright - Defense World
Bicara stock price target lowered to $44 at H.C. Wainwright By Investing.com - Investing.com Canada
Bicara stock price target lowered to $44 at H.C. Wainwright - Investing.com
Buy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial Stability - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2%Should You Sell? - MarketBeat
FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock By Investing.com - Investing.com UK
Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks
Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):